Table 1

The clinical characteristics of the controls and PD patients
PD Controls p value
N (M/F) 93, (50/43) 93, (47/46) 0.66
Age (yrs) 69.7 ± 8.9 69.6 ± 10.2 0.94
Body mass index (kg/m2) 22.3 ± 2.8 22.9 ± 3.1 0.18
* RLS, n (%) 5 (5.5) 2 (2.2) 0.44
Snoring (at least 2 days/week), n (%) 13 (14.0) 1 (1.1) 0.0010
RBDSQ-J ≥ 5, n (%) 27 (29.0) 8 (8.6) <0.001
RBDSQ-J ≥ 6, n (%) 16 (17.2) 2 (2.2) <0.001
RBDSQ-J 3.3 ± 2.5 1.7 ± 1.7 <0.001
PSQI global score 5.4 ± 3.7 4.5 ± 3.2 0.068
PSQI component score
  Sleep quality 1.0 ± 0.7 0.8 ± 0.6 0.024
  Sleep latency 0.8 ± 1.0 1.0 ± 1.0 0.40
  Sleep duration 0.8 ± 0.9 0.8 ± 0.9 0.62
  Habitual sleep efficiency 0.5 ± 0.9 0.5 ± 0.8 0.67
  Sleep disturbances 0.9 ± 0.6 0.8 ± 0.6 0.47
  Use of sleeping medication 0.7 ± 1.2 0.6 ± 1.1 0.48
  Daytime dysfunction 0.7 ± 0.9 0.2 ± 0.4 <0.001
ESS 6.6 ± 4.5 4.7 ± 3.0 <0.001
PDSS-2 total score 15.0 ± 9.7 9.1 ± 6.6 <0.001
PDSS-2 domain score
  Disturbed sleep 7.6 ± 3.5 5.6 ± 3.4 <0.001
  Motor symptoms at night 3.9 ± 4.1 1.8 ± 2.5 <0.001
  PD symptoms at night 3.5 ± 3.6 1.6 ± 2.1 <0.001
PDQ-39 summary index 29.1 ± 21.7 NA
PDQ-39 domain score
  Mobility 40.7 ± 33.9 NA
  ADL 33.0 ± 29.4 NA
  Emotional well-being 29.2 ± 25.8 NA
  Stigma 22.1 ± 22.4 NA
  Social support 12.0 ± 20.9 NA
  Cognition 23.6 ± 21.2 NA
  Communication 17.3 ± 20.8 NA
  Bodily discomfort 25.1 ± 24.8 NA
BDI-II 13.3 ± 9.3 8.5 ± 6.8 <0.001
PFS 2.8 ± 1.1 1.7 ± 0.8 <0.001
Levodopa (mg/day) 304.8 ± 135.5 NA
LED (mg/day) 385.1 ± 315.0 NA

PD, Parkinson’s disease; RLS, restless legs syndrome; RBDSQ-J, Japanese version of the REM sleep behavior disorder screening questionnaire; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; PDSS-2, Parkinson’s Disease Sleep Scale-2; PDQ-39, Parkinson’s Disease Questionnaire; BDI-II, Beck Depression Inventory-II; PFS, Parkinson Fatigue Scale; LED, Levodopa equivalent dose; NA, not applicable. *Data are missing for 4 controls and 2 PD patients.

The data are presented as the n (%) or the means ± SD. Statistically significant values (P < 0.05) are shown in bold.

Suzuki et al.

Suzuki et al. BMC Neurology 2013 13:18   doi:10.1186/1471-2377-13-18

Open Data